170
Participants
Start Date
January 31, 2010
Primary Completion Date
September 30, 2010
Lixivaptan
Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
Placebo
Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
Great Lakes Medical Research, Westfield
National Clinical Research - Richmond, Richmond
National Clinical Research - Norfolk, Inc., Norfolk
Raleigh Cardiology, Raleigh
In-Quest Medical Research, LLC, Duluth
Executive Health and Research Associates, Inc, Atlanta
Edgewater Medical Research Inc, Edgewater
Foundation/Research/Cardiovascular Specialists Lower Keys, Key West
Tampa Clinical Research, Tampa
Innovative Research of West Florida, Inc, Clearwater
Charlotte Heart Group Research Center, Port Charlotte
Mobile Heart Specialists, PC, Mobile
Clinical Research Limited, Canton
Dayton Heart Center, Dayton
Fox Valley Clinical Research Center, Aurora
Horizon Research, St Louis
Nea Clinic, Jonesboro
Cardiovascular Research Institute of Dallas, Dallas
East Texas Cardiology, Houston
Phoenix Clinical, Phoenix
Orange County Heart Institute and Research Center, Orange
Merced Heart Associates, Merced
Capitol Interventional Cardiology, Carmichael
Maine Research Associates, Auburn
Primary Care Cardiology Research, Inc, Ayer
Lead Sponsor
Cardiokine Biopharma, LLC
INDUSTRY
CardioKine Inc.
INDUSTRY